Cargando…

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy

NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however, NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Here, we show that NRAS(Q61)-mutated melanomas specific metabolic settings mediate cell sen...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGrail, Kimberley, Granado-Martínez, Paula, Esteve-Puig, Rosaura, García-Ortega, Sara, Ding, Yuxin, Sánchez-Redondo, Sara, Ferrer, Berta, Hernandez-Losa, Javier, Canals, Francesc, Manzano, Anna, Navarro-Sabaté, Aura, Bartrons, Ramón, Yanes, Oscar, Pérez-Alea, Mileidys, Muñoz-Couselo, Eva, Garcia-Patos, Vicenç, Recio, Juan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675737/ https://www.ncbi.nlm.nih.gov/pubmed/36402789 http://dx.doi.org/10.1038/s41467-022-34907-0

Ejemplares similares

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation
por: Granado-Martínez, Paula, et al.
Publicado: (2020)

Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway
por: Pérez-Alea, Mileidys, et al.
Publicado: (2016)

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

NRAS-mutant melanoma: current challenges and future prospect
por: Muñoz-Couselo, Eva, et al.
Publicado: (2017)

A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21(WAF1/CIP1)) Degradation
por: Esteve-Puig, Rosaura, et al.
Publicado: (2014)

Transcriptome of melanoma cells from two mouse models, Tyr:NRas(Q61K)and Tyr:Rack1-HA, Tyr:NRas(Q61K)
por: Campagne, Cécil, et al.
Publicado: (2017)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAF(V600E)
por: Esteve-Puig, Rosaura, et al.
Publicado: (2009)

Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS
por: Kinsler, Veronica A, et al.
Publicado: (2013)

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2017)

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
por: Vujic, Igor, et al.
Publicado: (2014)

P858: FUNCTIONAL STUDIES IN MULTIPLE MYELOMA CELL LINESWITH OVEREXPRESSION OF NRAS Q61R MUTATION
por: Liotti, Romano, et al.
Publicado: (2023)

Mutant NRAS(Q61) shares signaling similarities across various cancer types – potential implications for future therapies
por: Vujic, Igor, et al.
Publicado: (2014)

Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach
por: Jiang, Wei, et al.
Publicado: (2014)

NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas
por: Uguen, Arnaud, et al.
Publicado: (2015)

Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation
por: McReynolds, Lisa J., et al.
Publicado: (2019)

Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019)()
por: Morey-Olivé, Miriam, et al.
Publicado: (2020)

Manifestaciones cutáneas en contexto del brote actual de enfermedad por coronavirus 2019
por: Morey-Olivé, Miriam, et al.
Publicado: (2020)

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
por: Sanlorenzo, Martina, et al.
Publicado: (2018)

NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications
por: Angelino, Giulia, et al.
Publicado: (2016)

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
por: Kumar, Raj, et al.
Publicado: (2019)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signaling and malignant features in vitro and in vivo
por: Sesé, Marta, et al.
Publicado: (2017)

NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes
por: Yu, Ryan Timothy D., et al.
Publicado: (2020)

Liquid Biopsy with Detection of NRAS(Q61K) Mutation in Cerebrospinal Fluid: An Alternative Tool for the Diagnosis of Primary Pediatric Leptomeningeal Melanoma
por: Mastronuzzi, Angela, et al.
Publicado: (2022)

ODP465 BRAF V600 and NRAS Q61 mutations in thyroid fine-needle aspiration (FNA) with indeterminate cytology in Argentina
por: Repetto, Esteban M, et al.
Publicado: (2022)

Mrs. Einstein
por: McGrail, Anna
Publicado: (1998)

Surmortalité, COVID-19 et systèmes de santé au Canada
por: McGrail, Kimberlyn
Publicado: (2022)

Excess mortality, COVID-19 and health care systems in Canada
por: McGrail, Kimberlyn
Publicado: (2022)

Activated Mutant NRas(Q61K) Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism
por: Li, Ang, et al.
Publicado: (2012)

Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report
por: Mehrzad, Raman, et al.
Publicado: (2017)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

Income-related inequities: Cross-sectional analyses of the use of medicare services in British Columbia in 1992 and 2002
por: McGrail, Kimberlyn M
Publicado: (2008)

Spatial accessibility of primary health care utilising the two step floating catchment area method: an assessment of recent improvements
por: McGrail, Matthew R
Publicado: (2012)

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
por: Vujic, Igor, et al.
Publicado: (2016)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response
por: Lu, Jin-Ying, et al.
Publicado: (2016)

Mixed phenotype acute leukemia in a child associated with a NUP98‐NSD1 fusion and NRAS p.Gly61Arg mutation
por: Ganapathi, Shireen S., et al.
Publicado: (2021)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

What Is Bending the Cost Curve? An Exploration of Possible Drivers and Unintended Consequences
por: McGrail, Kimberlyn, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o1pk57vmsfchkp7n27t8teshd4